These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 33096610)

  • 1. The Circular Life of Human CD38: From Basic Science to Clinics and Back.
    Horenstein AL; Faini AC; Morandi F; Bracci C; Lanza F; Giuliani N; Paulus A; Malavasi F
    Molecules; 2020 Oct; 25(20):. PubMed ID: 33096610
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD38 as an immunotherapeutic target in multiple myeloma.
    Bonello F; D'Agostino M; Moscvin M; Cerrato C; Boccadoro M; Gay F
    Expert Opin Biol Ther; 2018 Dec; 18(12):1209-1221. PubMed ID: 30394809
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD38: A Target for Immunotherapeutic Approaches in Multiple Myeloma.
    Morandi F; Horenstein AL; Costa F; Giuliani N; Pistoia V; Malavasi F
    Front Immunol; 2018; 9():2722. PubMed ID: 30546360
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD38 as a therapeutic target.
    Stevenson GT
    Mol Med; 2006; 12(11-12):345-6. PubMed ID: 17380203
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD38-Specific Biparatopic Heavy Chain Antibodies Display Potent Complement-Dependent Cytotoxicity Against Multiple Myeloma Cells.
    Schütze K; Petry K; Hambach J; Schuster N; Fumey W; Schriewer L; Röckendorf J; Menzel S; Albrecht B; Haag F; Stortelers C; Bannas P; Koch-Nolte F
    Front Immunol; 2018; 9():2553. PubMed ID: 30524421
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nanobody-based CD38-specific heavy chain antibodies induce killing of multiple myeloma and other hematological malignancies.
    Schriewer L; Schütze K; Petry K; Hambach J; Fumey W; Koenigsdorf J; Baum N; Menzel S; Rissiek B; Riecken K; Fehse B; Röckendorf JL; Schmid J; Albrecht B; Pinnschmidt H; Ayuk F; Kröger N; Binder M; Schuch G; Hansen T; Haag F; Adam G; Koch-Nolte F; Bannas P
    Theranostics; 2020; 10(6):2645-2658. PubMed ID: 32194826
    [No Abstract]   [Full Text] [Related]  

  • 7. Anti-CD38 antibody therapy: windows of opportunity yielded by the functional characteristics of the target molecule.
    Chillemi A; Zaccarello G; Quarona V; Ferracin M; Ghimenti C; Massaia M; Horenstein AL; Malavasi F
    Mol Med; 2013 May; 19(1):99-108. PubMed ID: 23615966
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD38 antibodies in multiple myeloma: back to the future.
    van de Donk NWCJ; Richardson PG; Malavasi F
    Blood; 2018 Jan; 131(1):13-29. PubMed ID: 29118010
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD38 and Anti-CD38 Monoclonal Antibodies in AL Amyloidosis: Targeting Plasma Cells and beyond.
    Roccatello D; Fenoglio R; Sciascia S; Naretto C; Rossi D; Ferro M; Barreca A; Malavasi F; Baldovino S
    Int J Mol Sci; 2020 Jun; 21(11):. PubMed ID: 32531894
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The link between bone microenvironment and immune cells in multiple myeloma: Emerging role of CD38.
    Bolzoni M; Toscani D; Costa F; Vicario E; Aversa F; Giuliani N
    Immunol Lett; 2019 Jan; 205():65-70. PubMed ID: 29702149
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [CD38 antibodies in multiple myeloma].
    Moreaux J
    Med Sci (Paris); 2019 Dec; 35(12):1001-1004. PubMed ID: 31903907
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD38-targeting antibodies in multiple myeloma: mechanisms of action and clinical experience.
    Frerichs KA; Nagy NA; Lindenbergh PL; Bosman P; Marin Soto J; Broekmans M; Groen RWJ; Themeli M; Nieuwenhuis L; Stege C; Nijhof IS; Mutis T; Zweegman S; Lokhorst HM; van de Donk NWCJ
    Expert Rev Clin Immunol; 2018 Mar; 14(3):197-206. PubMed ID: 29465271
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Perspectives for the Development of CD38-Specific Heavy Chain Antibodies as Therapeutics for Multiple Myeloma.
    Bannas P; Koch-Nolte F
    Front Immunol; 2018; 9():2559. PubMed ID: 30459772
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma.
    Drent E; Groen RW; Noort WA; Themeli M; Lammerts van Bueren JJ; Parren PW; Kuball J; Sebestyen Z; Yuan H; de Bruijn J; van de Donk NW; Martens AC; Lokhorst HM; Mutis T
    Haematologica; 2016 May; 101(5):616-25. PubMed ID: 26858358
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combinatorial targeting of multiple myeloma by complementing T cell engaging antibody fragments.
    Geis M; Nowotny B; Bohn MD; Kouhestani D; Einsele H; Bumm T; Stuhler G
    Commun Biol; 2021 Jan; 4(1):44. PubMed ID: 33420283
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preliminary studies for an immunotherapeutic approach to the treatment of human myeloma using chimeric anti-CD38 antibody.
    Stevenson FK; Bell AJ; Cusack R; Hamblin TJ; Slade CJ; Spellerberg MB; Stevenson GT
    Blood; 1991 Mar; 77(5):1071-9. PubMed ID: 1995092
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fratricide of NK Cells in Daratumumab Therapy for Multiple Myeloma Overcome by
    Wang Y; Zhang Y; Hughes T; Zhang J; Caligiuri MA; Benson DM; Yu J
    Clin Cancer Res; 2018 Aug; 24(16):4006-4017. PubMed ID: 29666301
    [No Abstract]   [Full Text] [Related]  

  • 18. Retinoic acid-induced expression of CD38 antigen in myeloid cells is mediated through retinoic acid receptor-alpha.
    Drach J; McQueen T; Engel H; Andreeff M; Robertson KA; Collins SJ; Malavasi F; Mehta K
    Cancer Res; 1994 Apr; 54(7):1746-52. PubMed ID: 7511050
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Frontline Therapy for Fit MM Patients Should Include an Antibody.
    Voorhees P
    Clin Lymphoma Myeloma Leuk; 2020 Sep; 20 Suppl 1():S81-S83. PubMed ID: 32862881
    [No Abstract]   [Full Text] [Related]  

  • 20. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy.
    Gandhi UH; Cornell RF; Lakshman A; Gahvari ZJ; McGehee E; Jagosky MH; Gupta R; Varnado W; Fiala MA; Chhabra S; Malek E; Mansour J; Paul B; Barnstead A; Kodali S; Neppalli A; Liedtke M; Narayana S; Godby KN; Kang Y; Kansagra A; Umyarova E; Scott EC; Hari P; Vij R; Usmani SZ; Callander NS; Kumar SK; Costa LJ
    Leukemia; 2019 Sep; 33(9):2266-2275. PubMed ID: 30858549
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.